Castillo GD

Language: Spanish
References: 16
Page: 1-6
PDF size: 238.50 Kb.

Text Extraction

No abstract.

REFERENCES

1. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology. 2004;100(3):722-30

2. Giansily-Blaizot M, Schved J. Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. Ther Adv Hematol. 2017;8(12):345-52.

3. Park SC, Yeom SR, Han SK, Jo YM, Kim H Bin. Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage. Korean J Crit Care Med. 2017;32(04):333-9.

4. Neufeld EJ, Négrier C, Arkhammar P, Benchikh el Fegoun S, Simonsen MD, Rosholm A, Seremetis S. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015;29(Suppl 1):34-41.

5. Hedner U. General haemostatic agents-fact or fiction? Pathophysiol Haemost Thromb. 2002;32(Suppl 1):33-6.

6. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost. 2006; 32(Suppl 1):77-85.

7. Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematol Am Soc Hematol Educ Progr. 2010;153

8. Yampolsky N, Stofko D, Veznedaroglu E, Liebman K, Binning MJ. Recombinant factor VIIa use in patients presenting with intracranial hemorrhage. Springerplus. 2014;3:471.

9. Hedner UE. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol. 2003;1(2):112-9.

10. Rajpurkar M, Croteau SE, Boggio L, Cooper DL. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019;10:335-40.

11. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011 Apr 19;154(8):529-40.

12. Bastida JM, Cano-Mozo MT, Lopez-Cadenas F, Vallejo VE, Merchán S, Santos-Montón C, et al. Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies. Medicine (Baltimore). 2017;96(47):e8669.

13. Lin Y, Moltzan CJ, Anderson DR; National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med. 2012;22(6):383-94.

14. Colucci G, Helsing K, Biasiutti FD, Raio L, Schmid P, Tsakiris DA, et al. Standardized Management Protocol in Severe Postpartum Hemorrhage?: A Single-Center Study. Clin Appl Thromb. 2018;24(6):884-93.

15. Khouadja H, Rouissi W, Mahjoub M, Sakhri J, Beletaifa D, Jazia KB. Transfusion strategy for patients with severe postpartum hemorrhage: a retrospective study of 47 cases]. Pan Afr Med J. 2016;25:169.

16. Collins P, Abdul-Kadir R, Thachil J; Subcommittees on Women' s Health Issues in Thrombosis and Haemostasis and on Disseminated Intravascular Coagulation. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost.